In India, other alopecia areata is managed by dermatologists. Alopecia is the medical term for hair loss and covers a family of distinct conditions ranging from common androgenetic (male- or female-pattern) thinning to autoimmune alopecia areata, stress-driven telogen effluvium, and scarring inflammatory disorders. Roughly half of men show visible hair loss by age 50 and 40% of women by age 50, while alopecia areata affects about 2% of people at some point in life with peak onset under age 30.
Alopecia (ICD-10: L63, L64, L65, L66) is a broad term for partial or complete loss of hair from areas where it normally grows. Clinically and biologically the condition is split into non-scarring alopecia, in which the follicular ostia and stem cells remain intact and regrowth is biologically possible, and scarring (cicatricial) alopecia, in which the follicle is destroyed and replaced by fibrosis, making regrowth impossible. Within non-scarring alopecia, androgenetic alopecia (L64) reflects genetically programmed follicular miniaturization driven by dihydrotestosterone in androgen-sensitive scalp regions; alopecia areata (L63) is a T-cell-mediated autoimmune attack on the anagen hair bulb; telogen effluvium (L65.0) is a synchronized shift of follicles into the resting telogen phase triggered by a systemic stressor (illness, childbirth, surgery, weight loss, thyroid dysfunction, drugs); anagen effluvium (L65.1) is loss of actively growing hairs from chemotherapy, radiation, or toxin exposure. Scarring alopecias are subdivided by histology into lymphocytic (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, discoid lupus erythematosus), neutrophilic (folliculitis decalvans, dissecting cellulitis), and mixed forms.
The key symptoms of Other alopecia areata are: Gradual recession of the frontal hairline at the temples and progressive thinning over the crown in men — the classic Hamilton-Norwood male-pattern progression spanning 10-30 years., Diffuse widening of the central parting and reduced ponytail volume without true bitemporal recession in women — the Ludwig female-pattern presentation., Sudden appearance of one or more well-circumscribed coin-shaped patches of complete hair loss with preserved follicular openings and characteristic exclamation-mark hairs at the patch border — alopecia areata., Diffuse heavy shedding (100-300 hairs daily for weeks, particularly noticeable on the shower drain or pillow) starting 2-4 months after a triggering illness, childbirth, surgery, weight loss, or stress — telogen effluvium., Rapid global hair loss within 1-3 weeks of chemotherapy initiation — anagen effluvium., Progressive recession of the frontal and temporal hairline with thinning of the eyebrows and visible perifollicular erythema in postmenopausal women — frontal fibrosing alopecia., Painful, itchy, or burning scalp with red, scaly, or pustular patches of hair loss and loss of follicular ostia visible on dermoscopy — scarring alopecia..
Diagnosis starts with a focused history (onset, distribution, shedding versus thinning, triggers, family history, hair-care practices, drugs, comorbidities) and visual assessment of the scalp pattern. The clinician compares regions and looks for preserved or lost follicular ostia — the single most important sign separating non-scarring from scarring alopecia. A hair-pull test (gently extracting 30-60 hairs from three scalp regions) helps quantify active shedding: more than 6 telogen hairs per pull is abnormal. Trichoscopy (handheld polarized dermoscopy of the scalp) is now considered standard and demonstrates pattern-specific features: hair shaft diameter variation and miniaturization in androgenetic alopecia, exclamation-mark hairs and yellow dots in alopecia areata, perifollicular erythema and absent follicular ostia in scarring alopecia. Targeted laboratory testing includes complete blood count, ferritin (target above 70 ng/mL), TSH, vitamin D, and zinc; ANA, ENA, and androgen panels are added when systemic or hormonal disease is suspected. A 4 mm punch biopsy of the active edge — read by a dermatopathologist trained in horizontal sectioning — is the diagnostic standard for scarring alopecia and any presentation that cannot be classified clinically. Photography for serial comparison and validated severity scales (Sinclair score for female-pattern, SALT score for alopecia areata) anchor follow-up assessment.
Outlook depends on subtype, severity, and treatment timing. Androgenetic alopecia is progressive without treatment; with optimal therapy started early, more than 80% of men halt visible progression and 60-65% achieve cosmetically meaningful regrowth, and similar proportions of women stabilize or improve. Alopecia areata has a more variable course — roughly 30-50% of patchy cases regrow spontaneously within a year, but extensive (≥50% scalp) or long-standing disease has lower spontaneous remission rates and historically poor response to standard treatments; JAK inhibitors have improved outcomes substantially, with 35-40% achieving near-complete regrowth by 36-52 weeks. Telogen effluvium has an excellent prognosis with trigger correction; density returns to baseline within 6-12 months in 90% of cases. Scarring alopecias have the most guarded outlook: areas already destroyed cannot regrow, but timely diagnosis and treatment can arrest progression in 60-75% of patients. Outcomes in central centrifugal cicatricial alopecia and frontal fibrosing alopecia are best when treatment starts in early disease before significant follicular loss. Hair transplantation outcomes are durable in stable androgenetic alopecia (graft survival 85-95% at 1 year), provided ongoing medical therapy is continued to preserve native hair.
A dermatologist confirms the precise alopecia subtype with trichoscopy and, when indicated, scalp biopsy; identifies treatable systemic contributors; and selects evidence-based therapy tailored to subtype and severity. Specialist referral is essential before invasive treatments such as hair transplantation, which fails if applied to ongoing autoimmune or scarring disease.
Find specialists →Topical minoxidil: initial shed weeks 4-8, visible improvement months 4-6, plateau by 12 months. Oral finasteride: stabilization by 6 months, visible regrowth by 12 months in responders. JAK inhibitors for alopecia areata: initial regrowth by 12 weeks, maximum effect by 36-52 weeks. Telogen effluvium: resolution within 6-12 months of trigger correction. Hair transplantation: grafted hairs shed by week 4, regrow from month 3-4, final density by month 12-18. Scarring alopecias: stabilization within 6-12 months of effective therapy; existing density not recoverable.
Regular moderate aerobic exercise (150 minutes per week) improves stress and metabolic markers that influence shedding. Resistance training does not increase androgenic alopecia risk in men despite older claims about testosterone increases. Wear absorbent headbands rather than tight caps to reduce sweat retention and scalp irritation.
Choose a board-certified dermatologist with a specific hair-disorders interest, ideally trained at an academic alopecia clinic and familiar with current JAK-inhibitor protocols. For surgery, look for an ISHRS-affiliated hair-transplant surgeon with documented before-and-after results in your hair type and pattern. Avoid clinics that promise guaranteed regrowth or that recommend transplantation before subtype diagnosis.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Specialists who treat Other alopecia areata. Get expert guidance and personalized care.